A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma

SIMPLE SUMMARY: Sorafenib is the first approved targeted therapy for the treatment of advanced hepatocellular carcinoma (HCC). However, HCC resistance to sorafenib has greatly reduced its utility. Yes-associated protein (YAP) is overexpressed in cancers, including HCC. We observed a positive correla...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Mai-Huong T., Peng, Sue-Wei, Kuo, Yung-Che, Lin, Chun-Yen, Wu, Ming-Heng, Chuang, Chia-Hsien, Kao, Cheng-Xiang, Jeng, Han-Yin, Lin, Gee-Way, Ling, Thai-Yen, Chang, Te-Sheng, Huang, Yen-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345119/
https://www.ncbi.nlm.nih.gov/pubmed/34359714
http://dx.doi.org/10.3390/cancers13153812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345119/
https://www.ncbi.nlm.nih.gov/pubmed/34359714
http://dx.doi.org/10.3390/cancers13153812

Ejemplares similares